Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

A COPD drug from China draws $115M in venture funding

Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.

Read More

Published

on

Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad

Published

on

The FDA has been trying to mend fences with rare disease drug developers and patient groups since the departure of former Commissioner Marty Makary three months ago. But advisory committee meetings last week for Replimune and Capricor Therapeutics only created more confusion and frustration.

Continue Reading

Uncategorized

Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts

Published

on

HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.

Continue Reading

Uncategorized

STAT+: Moderna launches early trial of Ebola mRNA vaccine

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got a busy earnings week. Here’s the latest.

The need-to-know this morning

Novo vs. Lilly

The two GLP-1 giants have both reported earnings.

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got a busy earnings week. Here’s the latest.

The need-to-know this morning

Novo vs. Lilly

The two GLP-1 giants have both reported earnings.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Advertisement

Trending